Cacti Asset Management LLC Has $204,000 Position in Fresenius Medical Care AG (NYSE:FMS)

Cacti Asset Management LLC cut its holdings in Fresenius Medical Care AG (NYSE:FMS) by 73.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 9,000 shares of the company’s stock after selling 25,000 shares during the quarter. Cacti Asset Management LLC’s holdings in Fresenius Medical Care were worth $204,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of FMS. Wulff Hansen & CO. grew its holdings in Fresenius Medical Care by 1,809.0% in the 2nd quarter. Wulff Hansen & CO. now owns 343,429 shares of the company’s stock valued at $6,556,000 after buying an additional 325,439 shares during the last quarter. Moran Wealth Management LLC increased its position in shares of Fresenius Medical Care by 47.0% during the third quarter. Moran Wealth Management LLC now owns 233,376 shares of the company’s stock valued at $4,971,000 after purchasing an additional 74,621 shares during the period. Quantinno Capital Management LP raised its stake in shares of Fresenius Medical Care by 78.9% in the third quarter. Quantinno Capital Management LP now owns 110,078 shares of the company’s stock valued at $2,345,000 after purchasing an additional 48,554 shares in the last quarter. Triasima Portfolio Management inc. boosted its position in shares of Fresenius Medical Care by 27.4% during the 2nd quarter. Triasima Portfolio Management inc. now owns 85,430 shares of the company’s stock valued at $1,631,000 after acquiring an additional 18,360 shares in the last quarter. Finally, Franklin Resources Inc. increased its stake in shares of Fresenius Medical Care by 3.3% in the third quarter. Franklin Resources Inc. now owns 74,640 shares of the company’s stock valued at $1,490,000 after buying an additional 2,386 shares in the last quarter. Institutional investors and hedge funds own 8.37% of the company’s stock.

Fresenius Medical Care Trading Down 1.6 %

FMS traded down $0.36 during trading on Thursday, reaching $22.28. 102,242 shares of the company’s stock were exchanged, compared to its average volume of 353,043. The company’s fifty day moving average price is $22.19 and its 200-day moving average price is $20.63. The firm has a market capitalization of $13.07 billion, a PE ratio of 18.41, a P/E/G ratio of 0.96 and a beta of 0.93. Fresenius Medical Care AG has a fifty-two week low of $17.93 and a fifty-two week high of $24.31. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.02 and a current ratio of 1.37.

Analyst Upgrades and Downgrades

FMS has been the subject of several research reports. StockNews.com assumed coverage on shares of Fresenius Medical Care in a research report on Thursday, November 28th. They issued a “strong-buy” rating for the company. Truist Financial raised their price target on shares of Fresenius Medical Care from $22.00 to $23.00 and gave the company a “hold” rating in a report on Monday, October 7th. Bank of America raised Fresenius Medical Care from an “underperform” rating to a “neutral” rating in a report on Monday, December 2nd. Finally, Berenberg Bank began coverage on Fresenius Medical Care in a report on Wednesday, November 6th. They issued a “buy” rating and a $25.60 price target on the stock. One investment analyst has rated the stock with a sell rating, two have given a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Fresenius Medical Care currently has a consensus rating of “Hold” and an average price target of $24.30.

About Fresenius Medical Care

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.